Judges, Not Juries, Should Decide ‘Clear Evidence’ in FDA Labeling Preemption Cases, SCOTUS Rules

Drug Industry Daily
A A
Federal judges—and not juries—should say what constitutes “clear evidence” that the FDA would likely have rejected changes to a drug’s label, the Supreme Court ruled Monday in a decision that could have far-reaching impact on preemption cases.

To View This Article:

Login

Subscribe To Drug Industry Daily